113 related articles for article (PubMed ID: 37937329)
21. Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.
Pocock SJ; Ferreira JP; Packer M; Zannad F; Filippatos G; Kondo T; McMurray JJV; Solomon SD; Januzzi JL; Iwata T; Salsali A; Butler J; Anker SD
Eur J Heart Fail; 2022 Oct; 24(10):1869-1878. PubMed ID: 35796209
[TBL] [Abstract][Full Text] [Related]
22. Brain natriuretic peptide in acute myocardial infarction: a marker of cardio-renal interaction.
Moltrasio M; Cosentino N; De Metrio M; Rubino M; Cabiati A; Milazzo V; Discacciati A; Marana I; Bonomi A; Veglia F; Lauri G; Marenzi G
J Cardiovasc Med (Hagerstown); 2016 Nov; 17(11):803-9. PubMed ID: 26784574
[TBL] [Abstract][Full Text] [Related]
23. Prognostic relevance of B-type natriuretic peptide in patients with moderate mixed aortic valve disease.
Onishi H; Naganuma T; Izumo M; Ouchi T; Yuki H; Mitomo S; Nakamura S
ESC Heart Fail; 2022 Aug; 9(4):2474-2483. PubMed ID: 35543340
[TBL] [Abstract][Full Text] [Related]
24. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction.
van Veldhuisen DJ; Linssen GC; Jaarsma T; van Gilst WH; Hoes AW; Tijssen JG; Paulus WJ; Voors AA; Hillege HL
J Am Coll Cardiol; 2013 Apr; 61(14):1498-506. PubMed ID: 23500300
[TBL] [Abstract][Full Text] [Related]
25. B-type natriuretic peptide assessment in ambulatory heart failure patients: insights from IMPROVE HF.
Ambrosy AP; Fonarow GC; Albert NM; Curtis AB; Heywood JT; Mehra MR; O'Connor CM; Reynolds D; Walsh MN; Yancy CW; Gheorghiade M
J Cardiovasc Med (Hagerstown); 2012 Jun; 13(6):360-7. PubMed ID: 22472850
[TBL] [Abstract][Full Text] [Related]
26. A pooled analysis of multicenter cohort studies of (123)I-mIBG imaging of sympathetic innervation for assessment of long-term prognosis in heart failure.
Nakata T; Nakajima K; Yamashina S; Yamada T; Momose M; Kasama S; Matsui T; Matsuo S; Travin MI; Jacobson AF
JACC Cardiovasc Imaging; 2013 Jul; 6(7):772-84. PubMed ID: 23845574
[TBL] [Abstract][Full Text] [Related]
27. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.
Shah AM; Cikes M; Prasad N; Li G; Getchevski S; Claggett B; Rizkala A; Lukashevich I; O'Meara E; Ryan JJ; Shah SJ; Mullens W; Zile MR; Lam CSP; McMurray JJV; Solomon SD;
J Am Coll Cardiol; 2019 Dec; 74(23):2858-2873. PubMed ID: 31806129
[TBL] [Abstract][Full Text] [Related]
28. Influence of ejection fraction on the prognostic value of sympathetic innervation imaging with iodine-123 MIBG in heart failure.
Shah AM; Bourgoun M; Narula J; Jacobson AF; Solomon SD
JACC Cardiovasc Imaging; 2012 Nov; 5(11):1139-46. PubMed ID: 23153914
[TBL] [Abstract][Full Text] [Related]
29. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
30. Association of the frontal QRS-T angle with adverse cardiac remodeling, impaired left and right ventricular function, and worse outcomes in heart failure with preserved ejection fraction.
Selvaraj S; Ilkhanoff L; Burke MA; Freed BH; Lang RM; Martinez EE; Shah SJ
J Am Soc Echocardiogr; 2014 Jan; 27(1):74-82.e2. PubMed ID: 24075945
[TBL] [Abstract][Full Text] [Related]
31. Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF.
Mogensen UM; Køber L; Jhund PS; Desai AS; Senni M; Kristensen SL; Dukát A; Chen CH; Ramires F; Lefkowitz MP; Prescott MF; Shi VC; Rouleau JL; Solomon SD; Swedberg K; Packer M; McMurray JJV;
Eur J Heart Fail; 2018 Mar; 20(3):514-522. PubMed ID: 29193563
[TBL] [Abstract][Full Text] [Related]
32. Clinical Characteristics and Outcomes in Patients With Heart Failure: Are There Thresholds and Inflection Points in Left Ventricular Ejection Fraction and Thresholds Justifying a Clinical Classification?
Kondo T; Dewan P; Anand IS; Desai AS; Packer M; Zile MR; Pfeffer MA; Solomon SD; Abraham WT; Shah SJ; Lam CSP; Jhund PS; McMurray JJV
Circulation; 2023 Aug; 148(9):732-749. PubMed ID: 37366061
[TBL] [Abstract][Full Text] [Related]
33. Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction.
Linssen GC; Rienstra M; Jaarsma T; Voors AA; van Gelder IC; Hillege HL; van Veldhuisen DJ
Eur J Heart Fail; 2011 Oct; 13(10):1111-20. PubMed ID: 21642293
[TBL] [Abstract][Full Text] [Related]
34. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure.
Fonarow GC; Peacock WF; Phillips CO; Givertz MM; Lopatin M;
J Am Coll Cardiol; 2007 May; 49(19):1943-50. PubMed ID: 17498579
[TBL] [Abstract][Full Text] [Related]
35. Adverse Outcomes Associated With Interleukin-6 in Patients Recently Hospitalized for Heart Failure With Preserved Ejection Fraction.
Mooney L; Jackson CE; Adamson C; McConnachie A; Welsh P; Myles RC; McMurray JJV; Jhund PS; Petrie MC; Lang NN
Circ Heart Fail; 2023 Apr; 16(4):e010051. PubMed ID: 36896709
[TBL] [Abstract][Full Text] [Related]
36. Catheter ablation for non-paroxysmal atrial fibrillation accompanied by heart failure with preserved ejection fraction: feasibility and benefits in functions and B-type natriuretic peptide.
Yamauchi R; Morishima I; Okumura K; Kanzaki Y; Morita Y; Takagi K; Nagai H; Watanabe N; Furui K; Yoshioka N; Miyazawa H; Shimojo K; Imaoka T; Sakamoto G; Murohara T
Europace; 2021 Aug; 23(8):1252-1261. PubMed ID: 33693617
[TBL] [Abstract][Full Text] [Related]
37. IVC diameter in patients with chronic heart failure: relationships and prognostic significance.
Pellicori P; Carubelli V; Zhang J; Castiello T; Sherwi N; Clark AL; Cleland JG
JACC Cardiovasc Imaging; 2013 Jan; 6(1):16-28. PubMed ID: 23328557
[TBL] [Abstract][Full Text] [Related]
38. Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
Kristensen SL; Jhund PS; Køber L; McKelvie RS; Zile MR; Anand IS; Komajda M; Cleland JGF; Carson PE; McMurray JJV
JACC Heart Fail; 2015 Jun; 3(6):478-486. PubMed ID: 26046842
[TBL] [Abstract][Full Text] [Related]
39. Low and elevated B-type natriuretic peptide levels are associated with increased mortality in patients with preserved ejection fraction undergoing transcatheter aortic valve replacement: an analysis of the PARTNER II trial and registry.
Chen S; Redfors B; O'Neill BP; Clavel MA; Pibarot P; Elmariah S; Nazif T; Crowley A; Ben-Yehuda O; Finn MT; Alu MC; Vahl TP; Kodali S; Leon MB; Lindman BR
Eur Heart J; 2020 Feb; 41(8):958-969. PubMed ID: 31883339
[TBL] [Abstract][Full Text] [Related]
40. Combination of B-type natriuretic peptide and peak oxygen consumption improves risk stratification in outpatients with chronic heart failure.
Isnard R; Pousset F; Chafirovskaïa O; Carayon A; Hulot JS; Thomas D; Komajda M
Am Heart J; 2003 Oct; 146(4):729-35. PubMed ID: 14564330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
